September 25-27, 2021, the sixth “China BioMed Innovation and Investment Conference(CBIIC)” was successfully held in Suzhou. With cutting-edge scientific research and advanced medical projects, the scientific research team of Beroni Group was invited to attend the two important sections of “Clinical Trial Data Release” and “Medical Devices Roadshow” and make project presentations. The key date of the first-in-human phase I clinical trial of Beroni Group’s new anti-cancer drug PENAO in advanced solid tumors was disclosed for the first time at the conference.
Focusing on the theme of “Global Pharmaceutical Innovation in the New Era and New Pattern”, the conference provided participants with a platform for in-depth discussions on industrial policies, global pharmaceutical R&D trends and investment and financing trends to constantly promote innovation and development in the field of biomedicine. Hundreds of guests, including Libin Xiang, vice minister of Ministry of Science and Technology and academician of Chinese Academy of Sciences, Baige Zhao, vice director of the Foreign Affairs Committee of the 12th National People’s Congress, chairman of the Expert Committee of BRI International Think Tank of Chinese Academy of Social Sciences, and chairman of the Expert Committee of RDI, Siyuan Zhou, deputy director of the Drug Review Center of National Medical Products Administration, and some government officials, domestic authoritative scientists, financial investment elites and well-known entrepreneurs were invited to attend the conference.
With a rigorous and scientific project evaluation mechanism and a professional evaluation team consisting of leaders of relevant medical and health departments and top domestic scientists, the conference selected a number of high-quality medical projects with significant advantages and great commercial value to make presentations. Beroni Group’s two projects of “The First-in-human Phase I Clinical Trial of PENAO in Advanced Solid Tumors”and “CII-ArboViroPlex rRT-PCR assay” were selected.
At the “Clinical Trial Data Release” held on the 25th, the key date of the first-in-human phase I clinical trial of Beroni Group’s new anti-cancer drug PENAO was disclosed for the first time. PENAO enters tumor cells and accumulates in mitochondria where the arsenic molecule cross-links two amino acids(Cys160 and Cys25) on an enzyme known as adenine nucleotide translocase (ANT). This inactivates the enzyme and leads to cell proliferation arrest and ultimately apoptosis (death) of the cell. 27 patients enrolled with advanced solid tumors at phase I clinical trial. The results showed that the half-life of PENAO in humans was 3-4 days; the most appropriate dosage was 6mg/㎡, twice a week based on multiple index tests. And after given to patient with anaplastic astrocytoma at 6 mg/㎡/day PENAO over 30 weeks, it was found that the tumor area of the patient was reduced by using magnetic resonance imaging technology to monitor.
At the “Medical Devices Roadshow” held on the 27th, Miss. Jie Yang, project manager of the International R&D Center for Precision Medicine of Beroni Group, shared with the guests the CII-ArboViroPlex rRT-PCR assay. In recent years, the incidence of arbovirus, especially flavivirus, has increased year by year. After infection, the patient’s condition is serious and there is no specific medicine. Among them, Zika virus infection in pregnant women will cause fetal microcephaly. So a more efficient, faster, and more accurate method to detect and identify common flavivirus is needed urgently. Beroni’s CII-ArboViroPlex rRT – PCR assay developed by Beroni Group and Prof. Walter Ian Lipkin’s lab of Columbia University is a multiplex assay that can simultaneously test, detect and differentiate the Zika virus (ZIKV), Dengue virus (DENV), Chikungunya virus (CHIKV) and West Nile virus (WNV) by means of multiple rRT-PCR, and is approved for emergency use by US FDA and is CE certified. At present, it has filed 4 international invention patents. Beroni Group have received intention orders. Based on that, Beroni Group has established an Infection and Immunity Center and a Pathogenic Microorganism Discovery Platform for rapid diagnosis of pathogenic microorganisms.
With the urgent demand of global biomedical innovation, the investment scale of biomedical market continues to increase, innovative drugs and other innovative medical products has received great attention in the capital market. The two projects of Beroni Group introduced at the conference have huge potential value not only in the Chinese pharmaceutical market, but also in the international market.
